769 results on '"Atosiban"'
Search Results
2. Atosiban Versus Placebo in the Treatment of Late Threatened Pre-term Birth (APOSTEL 8)
- Author
-
ZonMw: The Netherlands Organisation for Health Research and Development, Nottingham University Hospitals NHS Trust, Amphia Hospital, St. Antonius Hospital, Deventer Ziekenhuis, Erasmus Medical Center, Flevoziekenhuis, Franciscus Gasthuis, Gelre Hospitals, Groene Hart Ziekenhuis, Isala, Leiden University Medical Center, Martini Hospital Groningen, Maxima Medical Center, Medical Centre Leeuwarden, Haaglanden Medical Centre, Maastricht University Medical Center, Medisch Spectrum Twente, OLVG, Radboud University Medical Center, Rijnstate Hospital, Spaarne Gasthuis, Tergooi Hospital, University Medical Center Groningen, UMC Utrecht, Diakonessenhuis, Utrecht, Ziekenhuisgroep Twente, Zuyderland Medical Centre, National Maternity Hospital, Ireland, and Martijn A. Oudijk, MD, PhD, Prof. Dr.
- Published
- 2024
3. Estimation of udder emptying based on milk constituents of strip samples after milking.
- Author
-
Jenni, Benjamin, Wellnitz, Olga, and Bruckmaier, Rupert M.
- Subjects
- *
FAT content of milk , *OXYTOCIN receptors , *MILK , *MILK proteins , *ELECTRIC conductivity , *DAIRY cattle , *FAT - Abstract
The list of standard abbreviations for JDS is available at adsa.org/jds-abbreviations-24. Nonstandard abbreviations are available in the Notes. Milk ejection disorders were induced by oxytocin receptor blockade. We tested the hypothesis that the degree of udder emptying at incomplete milk ejection can be estimated based on the concentration of various milk constituents in different milk fraction samples. To induce different levels of spontaneous udder emptying (SUE) 10 Holstein dairy cows were milked either with or without i.v. injection of the oxytocin receptor blocking agent atosiban (ATO). In ATOearly, 12 µg/kg BW ATO was injected immediately before and in ATOlate directly after a 1-min manual udder preparation. The normal milking routine served as the control treatment. In all 3 treatments the udder was completely emptied by the i.v. injection of 10 IU oxytocin (OT) at the end of spontaneous milk flow. During all experimental milkings 4 milk samples were taken in all treatments: at the start of udder preparation (foremilk; FM), immediately after cessation of spontaneous milk flow and cluster detachment by hand stripping (strip milk; SM), from spontaneous removed milk in bucket 1 (milk before OT; MBOT) and from the milk obtained after OT injection in bucket 2 (milk after OT; MAOT). Fat, protein, lactose, and electrolytes (Na, Cl, and K) were measured in each milk sample. In addition, electrical conductivity (EC) was determined in parallel to continuous milk flow recording. The treatments induced individual degrees of SUE; therefore, the final evaluations of data were based on SUE classes instead of treatments. The most pronounced differences of milk constituents at different degrees of SUE were found for the milk fat content. The fat content of SM and MBOT remained almost unchanged up to 60% SUE, but was considerably higher if >80% of the milk was spontaneously removed. The concentrations of Na and Cl were highest and of K lowest if less than 20% of milk was received in the different samples. The EC was higher in SM and MBOT if <20% of milk was received. In conclusion, the blockade of the OT effect influences primarily the fat content, which confirmed an OT-induced fat secretion during milking. Similar effects are likely found in situations of disturbed milk ejections, caused by a lack of or reduced release of OT in response to different degrees of tactile udder stimulation. Our results show that the measurement of fat content and the EC in SM samples collected after cluster detachment can be used to estimate the completeness of udder emptying. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Comparison of Intratympanic Oxytocin and Dexamethasone in Cisplatin Ototoxicity: An Experimental Study.
- Author
-
Taş, Burak Mustafa, Özel, Gökçe, Azman, Musa, Çakmak Karaer, Işıl, and Kılıç, Rahmi
- Subjects
- *
OTOACOUSTIC emissions , *ANTINEOPLASTIC agents , *OXYTOCIN , *CISPLATIN , *OTOTOXICITY - Abstract
Although it is widely used, there is still no valid treatment for ototoxicity caused by the antineoplastic drug cisplatin. In this study, we aimed to investigate the efficacy of intratympanic resveratrol and intratympanic dexamethasone treatment in cisplatin-induced ototoxicity. We also compared intratympanic atosiban (oxytocin antagonist) and oxytocin in cisplatin ototoxicity. In this study, 30 rats (60 ears) were used by separating into 5 groups. Cisplatin, oxytocin, dexamethasone, atosiban and 0.9% NaCl were administered intraperitoneally to all groups separately. Auditory Brainstem Response and Distortion Product Otoacoustic Emission tests were performed on all groups before and 72 h after the procedure. Pre-treatment values were higher than post-treatment values in all groups (p < 0.001). There was no significant prolongation of the post-treatment Auditory Brainstem Response I-IV interval in the oxytocin and dexamethasone groups (p > 0.05). There was no significant decrease in the frequencies of 2832 and 4004 after treatment in the oxytocin and dexamethasone group compared to pre-treatment in Distortion Product Otoacoustic Emission. As a result, it has been shown that intratympanic oxytocin may be an option that can be used in the treatment, although it is not as effective as dexamethasone in preventing cisplatin ototoxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Improvement of early miscarriage rates in women with adenomyosis via oxytocin receptor antagonist during frozen embryo transfer-a propensity score-matched study
- Author
-
Po-Wen Lin, Chyi-Uei Chern, Chia-Jung Li, Pei-Hsuan Lin, Kuan-Hao Tsui, and Li-Te Lin
- Subjects
Oxytocin receptor antagonist ,Atosiban ,Adenomyosis ,Frozen embryo transfer ,In vitro fertilization ,Gynecology and obstetrics ,RG1-991 ,Reproduction ,QH471-489 - Abstract
Abstract Background Dysfunctional uterine peristalsis seems to play a pivotal role in hindering embryo implantation among women diagnosed with adenomyosis. This research aims to investigate whether administering an oxytocin receptor antagonist during a frozen embryo transfer (FET) cycle using a hormone replacement therapy (HRT) protocol can enhance in vitro fertilization (IVF) outcomes for infertile women affected by adenomyosis. Methods Between January 2018 and June 2022, our reproductive center conducted IVF-FET HRT cycles for infertile women diagnosed with adenomyosis. Propensity score matching was employed to select matched subjects between the two groups in a 1:1 ratio. Following this, 168 women received an oxytocin receptor antagonist during FET, constituting the study group, while the matched 168 women underwent FET without this antagonist, forming the control group. We conducted comparative analyses of baseline and cycle characteristics between the two groups, along with additional subgroup analyses. Results The study group exhibited notably lower rates of early miscarriage compared to the control group, although there were no significant differences in clinical pregnancy rates, ongoing pregnancy rates, and live birth rates between the two groups. Multivariate analysis revealed a negative correlation between the use of oxytocin receptor antagonists and early miscarriage rates in women with adenomyosis. Subgroup analyses, categorized by age, infertility types, and embryo transfer day, showed a substantial decrease in early miscarriage rates within specific subgroups: women aged ≥ 37 years, those with secondary infertility, and individuals undergoing day 3 embryo transfers in the study group compared to the control group. Furthermore, subgroup analysis based on adenomyosis types indicated significantly higher clinical pregnancy rates, ongoing pregnancy rates and live birth rates in the study group compared to the control group among women with diffuse adenomyosis. Conclusions Administering an oxytocin receptor antagonist during FET may reduce the early miscarriage rates in women with adenomyosis.
- Published
- 2024
- Full Text
- View/download PDF
6. Improvement of early miscarriage rates in women with adenomyosis via oxytocin receptor antagonist during frozen embryo transfer-a propensity score-matched study.
- Author
-
Lin, Po-Wen, Chern, Chyi-Uei, Li, Chia-Jung, Lin, Pei-Hsuan, Tsui, Kuan-Hao, and Lin, Li-Te
- Subjects
- *
OXYTOCIN receptors , *ENDOMETRIOSIS , *EMBRYO implantation , *MISCARRIAGE , *HORMONE therapy - Abstract
Background: Dysfunctional uterine peristalsis seems to play a pivotal role in hindering embryo implantation among women diagnosed with adenomyosis. This research aims to investigate whether administering an oxytocin receptor antagonist during a frozen embryo transfer (FET) cycle using a hormone replacement therapy (HRT) protocol can enhance in vitro fertilization (IVF) outcomes for infertile women affected by adenomyosis. Methods: Between January 2018 and June 2022, our reproductive center conducted IVF-FET HRT cycles for infertile women diagnosed with adenomyosis. Propensity score matching was employed to select matched subjects between the two groups in a 1:1 ratio. Following this, 168 women received an oxytocin receptor antagonist during FET, constituting the study group, while the matched 168 women underwent FET without this antagonist, forming the control group. We conducted comparative analyses of baseline and cycle characteristics between the two groups, along with additional subgroup analyses. Results: The study group exhibited notably lower rates of early miscarriage compared to the control group, although there were no significant differences in clinical pregnancy rates, ongoing pregnancy rates, and live birth rates between the two groups. Multivariate analysis revealed a negative correlation between the use of oxytocin receptor antagonists and early miscarriage rates in women with adenomyosis. Subgroup analyses, categorized by age, infertility types, and embryo transfer day, showed a substantial decrease in early miscarriage rates within specific subgroups: women aged ≥ 37 years, those with secondary infertility, and individuals undergoing day 3 embryo transfers in the study group compared to the control group. Furthermore, subgroup analysis based on adenomyosis types indicated significantly higher clinical pregnancy rates, ongoing pregnancy rates and live birth rates in the study group compared to the control group among women with diffuse adenomyosis. Conclusions: Administering an oxytocin receptor antagonist during FET may reduce the early miscarriage rates in women with adenomyosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Atosiban interacts with growth hormones as adjuvants in frozen-thawed embryo transfer cycles.
- Author
-
Haixiao Chen, Jiali Cai, Xiaohua Sun, Lanlan Liu, Zhenfang Liu, Peng Gao, Xiaoming Jiang, and Jianzhi Ren
- Subjects
FROZEN human embryos ,EMBRYO transfer ,SOMATOTROPIN ,LOW-molecular-weight heparin - Published
- 2024
- Full Text
- View/download PDF
8. Comparative Evaluation of Alternative Deblocking Agents to Piperidine for Solid-Phase Synthesis of Peptides.
- Author
-
Petropavlovskaya, M. V., Palkeeva, M. E., Molokoedov, A. S., Ovchinnikov, M. V., and Sidorova, M. V.
- Subjects
- *
SOLID-phase synthesis , *PYRROLIDINE synthesis , *PEPTIDE synthesis , *SECONDARY amines , *APELIN - Abstract
The availability of piperidine, which is widely used for deblocking α-amine groups in solid-phase peptide synthesis using Fmoc methodology, is now significantly limited because this reagent is classified as a controlled substance. Therefore, a search for other available reagents capable of removing Fmoc-protection seems relevant. The suitability of three deblocking reagents based on secondary amines (4-methylpiperidine, pyrrolidine, and piperazine) for the solid-phase synthesis of peptides of various structures, i.e., atosiban (an analog of the neurohypophysial hormone oxytocin), metilin [an agonist of the apelin receptor (APJ)], and a fragment of the 11-19 amino-acid segment of the regulatory myosin light chain was comparatively assessed. These reagents were shown to be suitable alternatives to piperidine for the preparation of the physiologically active peptides being studied. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Investigation of the uterine modulating activities and mechanisms of Brachystegia eurycoma Harms (Leguminosae) methanol stem bark extract and fractions
- Author
-
Issa Onimisi Bello, Buniyamin A. Ayinde, Josephine O. Ofeimun, Fabian C. Amaechina, Nurkhalida Kamal, Christian W. Gruber, and Enitome E. Bafor
- Subjects
Brachystegia eurycoma ,Uterus ,Oxytocin ,Atosiban ,Uterine contractility ,Medicinal plant ,Science - Abstract
Dysfunctional labour (DL) is a major cause of maternal and neonatal deaths worldwide. The only clinically available drug is oxytocin which is about 50% effective. Therefore, the development of new effective drugs for DL is a necessity. The medicinal plant Brachystegia eurycoma Harms (synonym B. spiceaformis) is used for labour management in ethnomedicine. In the search for new lead compounds for DL therapy, the stem bark of B. eurycoma was subjected to bioactivity-guided fractionation procedures to elucidate its uterine-modulating activities and active compounds. B. eurycoma stem bark extract (BE) was fractionated via vacuum liquid chromatographic techniques. The fractionation process was guided by ex vivo uterine contractility assays on the mouse uterus, performed using spontaneous, oxytocin, and high KCl-induced contractility assays. Furthermore, the characterization of the chemical constituents was performed using nuclear magnetic resonance (NMR) and mass spectrometry (MS). BE produced dual effects on uterine contractility which was dependent on the reconstitution period. The freshly prepared crude extract (BEF) inhibited uterine contractility (IC50 amplitude = 0.8 ± 0.1 mg/ml; IC50 frequency = 1.4 ± 0.2 mg/ml). However, contractility was augmented when the reconstituted extract was stored for 24 h and beyond (BES) (EC50 amplitude = 0.2 ± 1.2 mg/ml; EC50 frequency = 0.91 ± 1.2 mg/ml). In addition, the compounds caffeine, genistein, and prunetin were identified from the potent BE fractions via the different spectroscopic and spectrometric tools. This study demonstrated a storage-dependent dual effect of BE where BEF induced inhibition and BES augmented uterine contractility. Findings from this study also suggest that caffeine and phytoestrogens contributed to the uterine-modulating activities of BE. Thus, further investigation of these compounds in combination and as separate lead compounds is required for DL therapeutic management.
- Published
- 2024
- Full Text
- View/download PDF
10. Effects of atosiban on clinical outcome in frozen-thawed embryo transfer: a propensity score matching study.
- Author
-
Ge, Caiyun, Zhang, Bo, Mao, Yanhong, Hong, Zhidan, Zhou, Chun, Wang, Yan, Wang, Mei, and Ma, Ling
- Subjects
- *
PROPENSITY score matching , *EMBRYO transfer , *MULTIPLE pregnancy , *EMBRYO implantation , *TREATMENT effectiveness , *INDUCED ovulation , *FERTILIZATION in vitro - Abstract
Purpose: To evaluate the effects of atosiban on clinical outcomes in patients undergoing frozen-thawed embryo transfer. Methods: The clinical data of 1093 infertile patients who underwent frozen-thawed embryo transfer in our center from January 2019 to December 2020 were retrospectively analyzed (control, 418; atosiban, 675). Propensity score matching (PSM) analysis identified 400 matched pairs of patients. The implantation rate, clinical pregnancy rate, live birth rate, biochemical pregnancy rate, abortion rate, multiple pregnancy rate, and ectopic pregnancy rate between the two groups were compared. Results: Before PSM, patients differed by infertility factors, number of transferred embryos, and endometrial preparation protocol (P < 0.05). After PSM, characteristics were similar in corresponding patients of the atosiban and control groups. After propensity score matching, we found that there was no significant difference in the implantation rate, clinical pregnancy rate, live birth rate, biochemical pregnancy rate, abortion rate, multiple pregnancy rate, and ectopic pregnancy rate in atosiban and control group (P > 0.05). Conclusion: Atosiban did not improve the clinical outcomes of infertile patients with frozen-thawed embryo transfer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Comparison of terbutaline and atosiban as tocolytic agents in intrauterine repair of myelomeningocele: a retrospective cohort study
- Author
-
Shirley Andrade Santos, Fernando Souza Nani, Elaine Imaeda de Moura, Diogo Lima de Carvalho, Guilherme Jorge Mattos Miguel, Cristiane Maria Federicci Haddad, Joaquim Edson Vieira, Victor Bunduki, Mário Henrique Burlacchini de Carvalho, Rossana Pulcineli Vieira Francisco, Daniel Dante Cardeal, and Hermann dos Santos Fernandes
- Subjects
Atosiban ,Perinatology ,Myelomeningocele ,Terbutaline ,Tocolysis ,Anesthesiology ,RD78.3-87.3 - Abstract
Background: Myelomeningocele (MMC) is a neural tube defect disease. Antenatal repair of fetal MMC is an alternative to postnatal repair. Many agents can be used as tocolytics during the in utero fetal repair such as β2-agonists and oxytocin receptor antagonists, with possible maternal and fetal repercussions. This study aims to compare maternal arterial blood gas analysis between terbutaline or atosiban, as tocolytic agents, during intrauterine MMC repair. Methods: Retrospective cohort study. Patients were divided into two groups depending on the main tocolytic agent used during intrauterine MMC repair: atosiban (16) or terbutaline (9). Maternal arterial blood gas samples were analyzed on three moments: post induction (baseline, before the start of tocolysis), before extubation, and two hours after the end of the surgery. Results: Twenty-five patients were included and assessed. Before extubation, the terbutaline group showed lower arterial pH (7.347 ± 0.05 vs. 7.396 ± 0.02 for atosiban, p = 0.006) and higher arterial lactate (28.33 ± 12.76 mg.dL−1 vs. 13.06 ± 6.35 mg.dL−1, for atosiban, p = 0.001) levels. Conclusions: Patients who received terbutaline had more acidosis and higher levels of lactate, compared to those who received atosiban, during intrauterine fetal MMC repair.
- Published
- 2024
- Full Text
- View/download PDF
12. In Utero Repair of Myelomeningocele: Atosiban Versus Terbutaline
- Author
-
Hermann dos Santos Fernandes, Attending Anesthetist
- Published
- 2022
13. The Effect of Selective Oxytocin Receptor Inhibitors on Endometriosis-related Pain (ENDOBAN)
- Published
- 2022
14. Effect of atosiban on in vitro fertilization pregnancy outcome among women with endometriosis in presence or absence of adenomyosis
- Author
-
Chih-Wei Lin, Meng-Hsing Wu, Yu-Lin Mau, Pei-Fang Su, and Huang-Tz Ou
- Subjects
Adenomyosis ,Atosiban ,Endometriosis ,Fertilization in vitro ,Pregnancy ,Gynecology and obstetrics ,RG1-991 - Abstract
Objective: This study aimed to assess the effect of atosiban on in vitro fertilization (IVF) pregnancy outcome among women with both endometriosis and adenomyosis, and compared it to that of patients with endometriosis but without adenomyosis and that of patients with tubal factor only. Materials and methods: 106 infertile women (176 embryo transfers) from a medical center in Taiwan were included in the analysis, where 34 (54), 34 (66), and 38 (56) cases (embryo transfers) were endometriosis without adenomyosis, endometriosis with adenomyosis, and tubal infertility factor only, respectively. Adenomyosis morphologies were classified using an ultrasound-based classification system. The logistic generalized estimating equation model was used to analyze the association between atosiban use and pregnancy outcomes. Results: The crude pregnancy rates for the endometriosis-only group were significantly higher than those for the endometriosis + adenomyosis group (i.e., biochemical pregnancy: 50.0% versus 29.7%, p = 0.041; ongoing pregnancy: 35.2% versus 16.9%, p = 0.038). Significantly higher chances of biochemical pregnancy and ongoing pregnancy among endometriosis patients without adenomyosis versus those with both endometriosis and adenomyosis were found (odds ratios [95% confidence intervals]: 2.981 [1.307, 6.803]; p = 0.009, 2.694 [1.151, 6.304]; p = 0.022). A significant positive association between atosiban use and biochemical pregnancy existed among endometriosis cases without adenomyosis (a 2.43-fold [1.01, 5.89] increase in successful pregnancy; p
- Published
- 2023
- Full Text
- View/download PDF
15. 基于 APOSTEL 系列研究早产保胎药物治疗临床 试验方法学的分析与探讨.
- Author
-
杜博冉, 史湘君, 张雪艳, 王爱华, 阴赪宏, and 冯 欣
- Subjects
- *
NIFEDIPINE , *DESIGN - Abstract
OBJECTIVE: To analyze and discuss the clinical trial methodology of tocolysis through analysis of the series of studies on assessment of perinatal outcome after sustained tocolysis in early labor (APOSTEL), so as to provide references for further research on tocolysis drugs in China. METHODS: Factors such as study type, exclusion criteria, outcome indicators, sample size and drug regimen in series of studies of APOSTEL were analyzed. Based on main results and conclusions of APOSTEL, the methodological design of clinical research on tocolysis drugs was analyzed and discussed. RESULTS: The series of studies of APOSTEL were designed as prospective and randomized controlled trials, the design of test was different from the guidelines in China in the diagnosis of pregnancy cycle, contraction intensity and cervical length. Patients were included with diagnosis of intermediate cervical length and fibronectin test. Exclusion criteria were used to exclude clinical indications of urgent delivery, neonates with congenital malformations and drug contraindications. In terms of the calculation of the expected number of participants, there was an improvement in the absolute proportion of national research applications, while international research was calculated based on relative proportion. Drug regimen of the experimental group and control group was mostly similar to the national guidelines, and the regimen design of drug delay therapy could be used as the reference. CONCLUSIONS: Referring to the series of studies of APOSTEL can further improve the relevant clinical design, and carry out design and implementation of high-quality clinical trials on tocolysis drugs for premature delivery according to the national conditions [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Approaches to Improve Endometrial Receptivity in Case of Repeated Implantation Failures
- Author
-
Makrigiannakis, Antonis, Makrygiannakis, Fanourios, and Vrekoussis, Thomas
- Subjects
Contraception/Reproduction ,Biotechnology ,Infertility ,Reproductive health and childbirth ,Good Health and Well Being ,repeated implantation failures ,HCG ,PBMC ,PRP ,microbiome ,G-CSF ,atosiban ,growth hormone - Abstract
Repeated implantation failures are a constant challenge in reproductive medicine with a significant impact both on health providers and on infertile couples. Several approaches have been proposed so far as effective; however, accumulative data have clarified that most of the treatment options do not have the evidence base for a generalized application to be suggested by the relevant societies. Implantation failures are attributed to either poor quality embryos or to defected endometrial receptivity. The current review aims to summarize in a systematic way all the new trends in managing RIF via interference with endometrial receptivity. The authors focus mainly, but not exclusively, on endometrial injury prior to embryo transfer and endometrial priming with autologous cells or biological agents. To this direction, a systematic search of the Pubmed database has been conducted taking into account the emerged evidence of the last two decades. All the suggested interventions are herein presented and analyzed in terms of reproductive outcomes. It is evident that properly powered and designed randomized trials are needed to support a new standard approach in RIF treatment that will safely be incorporated in national and international guidelines.
- Published
- 2021
17. PoC Study of OBE022 in Threatened Preterm Labour (PROLONG)
- Author
-
Scope International AG, Iqvia Pty Ltd, Cytel Inc., and PhinC Development
- Published
- 2021
18. Oxytocin Antagonist in Patients With Repeated Failure of Implantation
- Author
-
Onze Lieve Vrouw Hospital and Dr. Decleer Wim, gynecologist
- Published
- 2021
19. A randomized double blind comparison of atosiban in patients with recurrent implantation failure undergoing IVF treatment
- Author
-
Chuan Ling Tang, Qi Yue Li, Feng Lian Chen, Chen Ting Cai, Yue Yan Dong, Yuan Yuan Wu, Jian Zhi Yang, Mei Zhao, Feng Li Chi, Ling Hong, Ai Ai, Miao Xin Chen, Kun Ming Li, Xiao Ming Teng, and Zhi Qin Chen
- Subjects
Atosiban ,Recurrent implantation failure ,Fresh embryo transfer ,Live birth rate ,Endometrial peristalsis ,Gynecology and obstetrics ,RG1-991 ,Reproduction ,QH471-489 - Abstract
Abstract Background Patients with recurrent implantation failure (RIF) may have more uterine contractions. Several observational studies suggested that atosiban administration around embryo transfer resulted in higher pregnancy rates in RIF patients. This study aimed to evaluate the effect of atosiban given before fresh embryo transfer on pregnancy outcomes of women with RIF. Methods A prospective, randomized, double-blind controlled clinical trial was performed in IVF center of Shanghai First Maternity and Infant Hospital. According to a computer-generated randomization list, 194 infertile women with RIF received fresh embryo transfer between July 2017 and December 2019 were randomly allocated into the atosiban (n = 97) and the placebo (n = 97) groups. Women in the treatment group received atosiban intravenously about 30 min before embryo transfer with a bolus dose of 6.75 mg over one minute. Those in the placebo group received only normal saline infusion for the same duration. Results There was no significant difference in the live birth rate between the atosiban and placebo groups (42.3% vs 35.1%, P = 0.302, RR = 1.206 (0.844–1.723)). No significant differences were found between the two groups in the positive pregnancy test, clinical pregnancy, ongoing pregnancy, miscarriage, multiple pregnancy, ectopic pregnancy and implantation rates. Similar results were found when stratified by the number of embryos previously transferred, number of previous failed embryo transfers, frequency of endometrial peristalsis on embryo transfer day (≥ 3 waves/min) or serum estradiol (E2) on the day of hCG above the median level. And, there was no correlation between the serum E2 level on the day of hCG and the frequency of endometrial peristalsis on embryo transfer day. The frequency of endometrial peristalsis on embryo transfer day, total FSH/HMG dosage and duration were the significant factors which independently predicted the likelihood of a live birth. Conclusions These results suggested that atosiban treatment before fresh embryo transfer might not improve the live birth rate in RIF patients. Trial registration The study had been approved by the Institutional Review Board of the hospital (2017 ethics No.43) and was registered under Clinicaltrials.gov with an identifier NCT02893722.
- Published
- 2022
- Full Text
- View/download PDF
20. Efficacy of atosiban for repeated embryo implantation failure: A systematic review and meta-analysis.
- Author
-
Ruxin Wang, Haixia Huang, Yong Tan, and Guicheng Xia
- Subjects
EMBRYO implantation ,MULTIPLE pregnancy ,PREGNANCY outcomes ,REPRODUCTIVE technology ,ECTOPIC pregnancy ,LONGITUDINAL method - Abstract
Background: Repeated embryo implantation failure (RIF) posed a significant challenge in assisted reproduction. Evidence of its therapeutic effectiveness including atosiban used around embryo transfer to improve pregnancy outcomes in RIF patients undergoing in vitro fertilization-embryo transfer (IVFET) remained inconsistent. This study aimed to explore the efficacy of atosiban on pregnancy outcomes of patients with RIF who received IVF-ET. Methods: The research was designed using the PICOS format. A systematic search of four English databases, PubMed, EMBASE, Web of Science, Cochrane Library, and one Chinse database, China National Knowledge Infrastructure (CNKI) was conducted. The time range was from inception to December 10, 2022. Then trials comparing the efficacy of atosiban and control group on pregnancy outcomes in RIF patients who receive IVF-ET were included. Subgroup analysis and sensitivity analysis were performed to reduce the influence of heterogeneity between included studies. Risk ratio (RR) and 95% confidence interval (CI) were calculated. The main outcome measure was clinical pregnancy rate (CPR). For the analyses, StataMP 17.0 (Stata Corporation, USA) was used. Results: Two prospective randomized controlled trials (RCTs), one prospective cohort study and four retrospective cohort studies were included. Our results showed that atosiban was associated with higher clinical pregnancy rate (RR=1.54, 95% CI: 1.365-1.735, P < 0.001, I2 = 0.0%). The results of subgroup analysis based on study types (prospective randomized controlled clinical trial, retrospective cohort study and prospective cohort study) showed that in all types of studies, CPR of atosiban group was significantly higher than controlled group. The results of subgroup analysis based upon the diagnostic criteria of number of previous embryo transfer failures showed that the intervention of atosiban improved the CPR whether in participants with 2 previous ET failures or in participants with 3 previous ET failures. Nevertheless, the incidence of ectopic pregnancy, multiple pregnancy, and miscarriages were not significantly different between the case and control groups. Conclusion: For women who are undergoing IVF-ET and have experienced repeated embryo implantation failure, atosiban may be an important factor in enhancing pregnancy outcomes. To confirm this conclusion, more thorough, prospective randomized controlled studies of sizable sample sizes with well design are required. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. 阿托西班对反复种植失败患者冻融胚胎移植临床结局的影响.
- Author
-
张园, 姜超, 蒋春艳, 钱易, 袁纯, 舒黎, 冒韵东, 刘嘉茵, 刁飞扬, and 马翔
- Abstract
Objective: To investigate the effects of atosiban on the pregnancy outcome of frozen-thawed embryo transfer in patients with repeated implantation failure with different etiologies. Methods: From January 2019 to January 2021, the patients diagnosed with repeated implantation failure in their frozen-thawed embryo transfer cycles were selected, and the clinical data of 230 patients were included by the propensity score matching method. Patients were divided into the atosiban group and the control group, according to whether atosiban was used on the day of embryo transfer. A small dose of 6.75 mg (0.9 mL) of atosiban was injected intravenously 30 minutes before embryo transfer in the atosiban group (n=115), while the control group (n=115) did not use. The implantation rate, clinical pregnancy rate, ectopic pregnancy rate, miscarriage rate, preterm birth rate and live birth rate were compared between the two groups. The different causes of repeated implantation failure (endometriosis, immunological or coagulation abnormalities, unknown causes, complex factors and other factors) were analyzed in subgroups, and the differences of clinical outcomes between the two groups were compared. Results: No significant differences were found in the implantation rate, clinical pregnancy rate, ectopic pregnancy rate, miscarriage rate, preterm birth rate and live birth rate between the two groups (both P>0.05). Multivariate analysis showed that there was a significant correlation between the type of transferred embryos and the live birth rate (P=0.001). The subgroup analysis of the different causes of repeated implantation failure showed that in the subgroup of endometriosis, the use of atosiban could significantly reduce the miscarriage rate (P=0.036), but does not increase the live birth rate (P=0.757). Conclusions: The use of atosiban cannot improve the clinical outcome of frozenthawed embryo transfer cycle in patients with repeated implantation failure, and does not improve the live birth rate. It is not recommended to use atosiban without clinical indications. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. A case of severe non-cardiogenic pulmonary edema in a woman treated with atosiban for preterm labor.
- Author
-
CHEN, Y., JIANG, C.-Y., DENG, Z.-W., DUAN, Z.-X, SHU, Y.-L., and ZHOU, J.-L.
- Abstract
BACKGROUND: A 27-year-old primigravid woman with a triamniotic pregnancy presented with preterm labor at 29 weeks of gestation and acute severe pulmonary edema after treatment with atosiban. CASE REPORT: The severe symptoms and hypoxemia of the patient led to emergency hysterotomy and intensive care unit hospitalization. CONCLUSIONS: This clinical case prompted us to review the existing literature to examine studies on differential diagnoses in pregnant women with acute dyspnea. The possible pathophysiological mechanisms of this condition and the management of acute pulmonary edema are worth discussing. [ABSTRACT FROM AUTHOR]
- Published
- 2023
23. Atosiban-induced acute pulmonary edema: A rare but severe complication of tocolysis
- Author
-
Zuwei Yang, Wei Wu, Yi Yu, and Haiyan Liu
- Subjects
Atosiban ,Acute pulmonary edema ,Pregnancy ,Preterm birth ,Tocolytics ,Hypoxia ,Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
Background: Atosiban is commonly used to delay premature labor in pregnant women and is thought to have few side effects. Objectives: To report a case of acute pulmonary edema (APE) following administration of atosiban and conduct a systematic review to identify common characteristics and risk factors of atosiban-associated APE. Methods: Searches were performed in Pubmed, Embase, and Web of Science using the keyword “Atosiban” combined with the terms “Pulmonary edema” or “Dyspnea” or “Hypoxia” on 9th July 2022. Only case reports of atosiban-associated APE were included without language restrictions. Data were extracted from the reports, and median, range, and percentages were calculated as applicable. The risk of bias was assessed using the Joanna Briggs Institute critical appraisal checklist for case reports. Results: Seven cases of atosiban-associated APE were included in the systematic review, including our case. APE occurred at a median gestational age of 32 + 6 weeks. Most patients were nulliparous (6/7, 85.7%) and were in multiple pregnancies (5/7, 71.4%). All patients were prescribed antenatal corticosteroids and tocolytics, with three (42.9%) receiving only atosiban and four (57.1%) receiving atosiban and other tocolytics. The median interval from starting atosiban administration to APE onset was about 40 h, and three patients (42.9%) showed symptoms 2–10 h after the end of atosiban treatment. Radiographic examinations (chest X-ray and/or computer tomography scan) confirmed APE in all patients and pleural effusion in four patients (57.1%). Five patients (71.4%) underwent emergency cesarean section, one patient (14.3%) with twin pregnancy had vaginal delivery with the help of suction cup and forceps, and another patient (14.3%) continued the pregnancy. All patients recovered well after administration of oxygen, diuresis, and other supportive therapy. Conclusion: Atosiban may cause acute pulmonary edema in patients with underlying risk factors. This complication remains rare, but caution during tocolytic treatment using atosiban is recommended.
- Published
- 2023
- Full Text
- View/download PDF
24. Effect of Oxytocin Antagonists on Implantation Success Rates of Frozen-thawed Embryo Transfer
- Author
-
Yeditepe University
- Published
- 2020
25. A Randomized Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban for Women in Spontaneous Preterm Labour
- Author
-
PPD DEVELOPMENT, LP
- Published
- 2020
26. Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies (ARIOS)
- Author
-
PPD DEVELOPMENT, LP
- Published
- 2020
27. Mechanism of Oxytocin-Induced Contraction in Rat Gastric Circular Smooth Muscle.
- Author
-
Alqudah, Mohammad, Razzaq, Rima Abdul, Alfaqih, Mahmoud A., Al-Shboul, Othman, Al-Dwairi, Ahmed, and Taha, Safa
- Subjects
- *
MYOSIN light chain kinase , *CELL receptors , *SMOOTH muscle contraction , *SMOOTH muscle , *RYANODINE receptors , *PROTEIN kinase inhibitors , *PHOSPHOLIPASES , *CALMODULIN - Abstract
Oxytocin produces an excitatory effect on gastric muscle through the activation of receptors present on stomach smooth muscle cells. However, the intracellular mechanisms that mediate oxytocin excitatory effects are still largely unknown. Therefore, we aimed to investigate the signaling pathways involved in oxytocin-induced contractions in gastric smooth muscle, shedding light on phospholipase C (PLC)-β1 signaling and its downstream molecules, including inositol 1,4,5- trisphosphate (IP3) and myosin light chain kinase (MLCK). The contractions of gastric smooth muscle from male rats were measured in an organ bath set up in response to exogenous oxytocin 10−7 M, in the presence and absence of inhibitors of the indicated signaling molecules. Oxytocin (10−9–10−5 M) induced dose-dependent stomach smooth muscle contraction. Pre-incubation with atosiban, an oxytocin receptor inhibitor, abolished the oxytocin-induced contraction. Moreover, PLC β1 inhibitor (U73122) and IP3 inhibitor Xestospongin C inhibited oxytocin-induced muscle contraction to various degrees. Verapamil, a calcium channel blocker, inhibited oxytocin-induced contraction, and pre-incubation of the strips, with both verapamil and Xestospongin C, further inhibited the excitatory effect of oxytocin. Chelation of intracellular calcium with BAPT-AM (1,2-bis-(o-aminophenoxy) ethane-N,N,N′,N′-tetraacetic acid) significantly inhibited the effect of oxytocin on muscle contraction. Finally, pre-incubation of the strips with the Ca2+/calmodulin-dependent protein kinase selective inhibitor STO-609 significantly inhibited the contraction induced by oxytocin. These results suggest that oxytocin directly stimulates its cell surface receptor to activate PLC β1, which in turn liberates IP3, which eventually elevates intracellular calcium, the prerequisite for smooth muscle contraction. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. A randomized double blind comparison of atosiban in patients with recurrent implantation failure undergoing IVF treatment.
- Author
-
Tang, Chuan Ling, Li, Qi Yue, Chen, Feng Lian, Cai, Chen Ting, Dong, Yue Yan, Wu, Yuan Yuan, Yang, Jian Zhi, Zhao, Mei, Chi, Feng Li, Hong, Ling, Ai, Ai, Chen, Miao Xin, Li, Kun Ming, Teng, Xiao Ming, and Chen, Zhi Qin
- Subjects
- *
HUMAN in vitro fertilization , *EMBRYO implantation , *FERTILIZATION in vitro , *EMBRYO transfer , *MULTIPLE pregnancy , *PREGNANCY outcomes - Abstract
Background: Patients with recurrent implantation failure (RIF) may have more uterine contractions. Several observational studies suggested that atosiban administration around embryo transfer resulted in higher pregnancy rates in RIF patients. This study aimed to evaluate the effect of atosiban given before fresh embryo transfer on pregnancy outcomes of women with RIF. Methods: A prospective, randomized, double-blind controlled clinical trial was performed in IVF center of Shanghai First Maternity and Infant Hospital. According to a computer-generated randomization list, 194 infertile women with RIF received fresh embryo transfer between July 2017 and December 2019 were randomly allocated into the atosiban (n = 97) and the placebo (n = 97) groups. Women in the treatment group received atosiban intravenously about 30 min before embryo transfer with a bolus dose of 6.75 mg over one minute. Those in the placebo group received only normal saline infusion for the same duration. Results: There was no significant difference in the live birth rate between the atosiban and placebo groups (42.3% vs 35.1%, P = 0.302, RR = 1.206 (0.844–1.723)). No significant differences were found between the two groups in the positive pregnancy test, clinical pregnancy, ongoing pregnancy, miscarriage, multiple pregnancy, ectopic pregnancy and implantation rates. Similar results were found when stratified by the number of embryos previously transferred, number of previous failed embryo transfers, frequency of endometrial peristalsis on embryo transfer day (≥ 3 waves/min) or serum estradiol (E2) on the day of hCG above the median level. And, there was no correlation between the serum E2 level on the day of hCG and the frequency of endometrial peristalsis on embryo transfer day. The frequency of endometrial peristalsis on embryo transfer day, total FSH/HMG dosage and duration were the significant factors which independently predicted the likelihood of a live birth. Conclusions: These results suggested that atosiban treatment before fresh embryo transfer might not improve the live birth rate in RIF patients. Trial registration: The study had been approved by the Institutional Review Board of the hospital (2017 ethics No.43) and was registered under Clinicaltrials.gov with an identifier NCT02893722. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. Simulated Y-site compatibility of atosiban acetate with selected intravenous drugs.
- Author
-
Jiménez-Lozano, Inés, Larrosa-García, María, Boix-Montañés, Antoni, Bautista, Susana Clemente, and Poy, Maria Josep Cabañas
- Subjects
- *
PARTICULATE matter , *ACETATES , *OMEPRAZOLE , *DRUGS , *AMPICILLIN , *INTRAVENOUS therapy , *INCOMPATIBLES (Pharmacy) , *ACETIC acid , *PITUITARY hormones - Abstract
Objective: The physical compatibility of atosiban and selected drugs during simulated Y-site administration was evaluated. We also searched for any compatibility predictions regarding its physicochemical properties.Study Design: Test admixtures were prepared by mixing 5 mL of each study drug solution with 5 mL of atosiban solution in a 1:1 ratio to simulate Y-site infusion. Assessments were made immediately after mixing (baseline), and at 0.5, 1, and 3 h. Visual incompatibility was defined as a presence of haze or any visible particulate matter, gas formation, or colour change. Turbidity and pH variation of the admixtures were also assessed using instrumental methods.Results: None of the admixtures used with atosiban exhibited visual changes and no incompatibility regarding instrumental methods were observed, because no admixture had an increase of 0.5 nephelometric turbidity units, and no pH change was above one unit when compared to baseline. However, the pH of ampicillin and omeprazole admixtures fell outside of the atosiban stability range.Conclusions: Our study showed no physical incompatibility between atosiban and the test drugs in terms of visual changes or nephelometric and pH measurements. However, we recommend against atosiban and ampicillin or omeprazole coadministration until complementary compatibility studies are performed. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
30. Oxidative Stress in Women Treated With Atosiban for Impending Preterm Birth
- Published
- 2019
31. Impacts of Tocolytics on Maternal and Neonatal Glucose Levels in Women With Gestational Diabetes Mellitus.
- Author
-
Hong S, Seol HJ, Lee J, Hwang HS, Sung JH, Kwon JY, Lee SM, Seong WJ, Choi SR, Kim SC, Kim HS, Lee SJ, Choi SK, Lee KA, Ko HS, and Park HS
- Subjects
- Humans, Female, Pregnancy, Retrospective Studies, Adult, Infant, Newborn, Logistic Models, Hyperglycemia drug therapy, Odds Ratio, Obstetric Labor, Premature drug therapy, Pregnancy Outcome, Republic of Korea, Diabetes, Gestational drug therapy, Tocolytic Agents therapeutic use, Tocolytic Agents adverse effects, Blood Glucose analysis, Nifedipine therapeutic use, Nifedipine adverse effects, Hypoglycemia, Ritodrine therapeutic use, Ritodrine adverse effects, Vasotocin analogs & derivatives, Vasotocin therapeutic use, Vasotocin adverse effects
- Abstract
Background: We investigated the impacts of tocolytic agents on maternal and neonatal blood glucose levels in women with gestational diabetes mellitus (GDM) who used tocolytics for preterm labor., Methods: This multi-center, retrospective cohort study included women with GDM who were admitted for preterm labor from twelve hospitals in South Korea. We excluded women with multiple pregnancies, anomalies, overt DM diagnosed before pregnancy or 23 weeks of gestation, and women who received multiple tocolytics. The patients were divided according to the types of tocolytics; atosiban, ritodrine, and nifedipine group. We collected baseline maternal characteristics, pregnancy outcomes, maternal glucose levels during hospitalization, and neonatal glucose levels. We compared the frequency of maternal hyperglycemia and neonatal hypoglycemia among three groups. A multivariate logistic regression analysis was performed to evaluate the contributing factors to the occurrence of maternal hyperglycemia and neonatal hypoglycemia., Results: A total of 128 women were included: 44 (34.4%), 51 (39.8%), and 33 (25.8%) women received atosiban, ritodrine, and nifedipine, respectively. Mean fasting blood glucose (FBG) (112.3, 109.6, and 89.5 mg/dL, P < 0.001) and 2-hour postprandial glucose (PPG2) levels (145.4, 148.3, and 116.5 mg/dL, P = 0.004) were significantly higher in atosiban and ritodrine group than those in nifedipine group. Even after adjusting for covariates including antenatal steroid use, gestational age at admission, and pre-pregnancy body mass index, there was an increased risk of high maternal mean FBG (≥ 95 mg/dL) and PPG2 (≥ 120 mg/dL) levels in the atosiban and ritodrine group than in nifedipine group. The atosiban and ritodrine groups are also at increased risk of neonatal hypoglycemia (< 47 mg/dL) compared to the nifedipine group with the odds ratio of 4.58 and 4.67, respectively ( P < 0.05)., Conclusion: There is an increased risk of maternal hyperglycemia and neonatal hypoglycemia in women with GDM using atosiban and ritodrine tocolytics for preterm labor compared to those using nifedipine., Competing Interests: Hyun Soo Park and Hyun-Joo Seol participated in the Tractocile (atosiban) Advisory Board and received consulting fees from Ferring Pharmaceuticals Korea on October 24, 2023. Other authors have no potential conflicts of interest., (© 2024 The Korean Academy of Medical Sciences.)
- Published
- 2024
- Full Text
- View/download PDF
32. Four kinds of tocolytic therapy for preterm delivery: Systematic review and network meta‐analysis.
- Author
-
Xiong, Zhihui, Pei, Shuping, and Zhu, Zhen
- Subjects
- *
DRUG efficacy , *ONLINE information services , *MEDICAL databases , *RITODRINE , *PREMATURE infants , *META-analysis , *MEDICAL information storage & retrieval systems , *SYSTEMATIC reviews , *TOCOLYTIC agents , *EVIDENCE-based medicine , *INDOMETHACIN , *MEDLINE , *DATA analysis software , *HEALTH self-care , *NIFEDIPINE , *EVALUATION - Abstract
What is known and objective: Premature birth affects more than 15 million infants, as well as mothers and families around the world. With the relaxation of the two‐child policy, the problem of premature birth has become relatively prominent in China. According to statistics, China had a birth population of 15.23 million in 2018, with a considerably large number of premature births. This study aims to evaluate the efficacy and safety of tocolysis in the treatment of preterm delivery, provide clinical evidence for medical staff and promote the self‐management of patients with premature births. Methods: Four English databases (PubMed, Embase, Cochrane Library and Web of Science) were retrieved by computer, the retrieval time was from the establishment of each database to November 2021, and the randomized controlled trials for the treatment of preterm delivery were screened according to the pre‐set natriuretic exclusion criteria. After literature screening, data selection and risk of bias evaluation were independently conducted by two researchers. R 4.1.1 and Stata 17.0 software were used for statistical analysis. Results and discussion: A total of 44 RCTs were included, including 6939 patients. The results of network meta‐analysis reveal that in terms of effectiveness, indomethacin was the most effective intervention measure, followed by nifedipine, and the difference was statistically significant; regarding safety, nifedipine was the safest intervention measure, followed by indomethacin, and the difference was statistically significant; and in respect of adverse reactions, ritodrine had the highest probability, and the difference was statistically significant. What is new and conclusion: Nifedipine may be better for delayed delivery and less likely to produce adverse pregnancy outcomes, followed by indomethacin. Limited by the number and quality of recipient studies, the aforementioned conclusions need to be verified through more high‐quality studies. At the same time, the focus should be on patients with twin pregnancy and patients with clinical manifestations of extreme preterm delivery. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
33. Administration of oxytocin antagonist at the same time as using a Foley catheter with cotton swab before embryo transfer for cervical stenosis
- Author
-
Heesuk Chae
- Subjects
Embryo transfer ,Cervical stenosis ,Foley catheter ,Atosiban ,Gynecology and obstetrics ,RG1-991 ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background Embryo transfer without difficulty in a patient with cervical stenosis can be a great challenge for in vitro fertilization (IVF). We report a successful pregnancy following a frozen thawed embryo transfer after administration of an oxytocin antagonist at the same time as using a Foley catheter with cotton swab in a patient with refractory cervical stenosis. Case presentation A 40-year-old woman undergoing IVF. The patient’s previous embryo transfers were difficult. For every transfer, uterine manipulation was needed, force was required, and dilatation was necessary. A Foley catheter with a cotton swab was inserted into the cervical canal, atosiban was administered at the same time, and the Foley catheter was removed immediately before embryo transfer. A smooth transfer was performed without bleeding, force, uterine manipulation, or cervical dilator. The patient became pregnant and delivered by cesarean section at term. Conclusion This method is effective in performing atraumatic embryo transfer in patients with cervical stenosis.
- Published
- 2021
- Full Text
- View/download PDF
34. Pregnancy and neonatal outcomes of hyperglycemia caused by atosiban administration during pregnancy
- Author
-
Hyun Jin Ko, Seong Yeon Hong, and Jin Young Bae
- Subjects
atosiban ,preterm labor ,maternal hyperglycemia ,neonatal hypoglycemia ,Gynecology and obstetrics ,RG1-991 - Abstract
It is known that atosiban has fewer side effects than conventional tocolytics. In clinical practice, however, hyperglycemia can be commonly observed in mothers who have been administered atosiban. Therefore, we investigated whether intravenous atosiban injection actually causes hyperglycemia and how these changes affect newborns. From December 2015 to July 2018, a retrospective study was conducted on 96 mothers who were diagnosed with preterm labor and were administered atosiban at our institution. Maternal blood glucose was measured and compared before and during the administration of atosiban. The paired t-test, independent samples t-test, Chi-square test and Fisher’s exact test were performed using SPSS version 21.0. A statistically significant increase in fasting blood glucose levels was observed during the administration of atosiban, compared with random blood glucose levels before administration (110.7 mg/dL vs. 86.3 mg/dL). The mean postprandial blood glucose level during administration was 170.75 mg/dL. Gestational diabetes, twin pregnancy, preeclampsia, and polyhydramnios did not significantly affect the degree of blood glucose increase. Statistically significant hypoglycemia was observed after performing a neonatal blood test immediately after birth from mothers who used atosiban. The neonates from the group with elevated maternal blood glucose levels exceeding 20 mg/dL showed lower blood glucose levels. No serious side effects other than hypoglycemia were observed. Atosiban administration in pregnant women results in significantly elevated maternal blood glucose, which results in hypoglycemia in neonates after birth. Therefore, neonates from mothers who received atosiban require a blood glucose test and close monitoring after birth.
- Published
- 2021
- Full Text
- View/download PDF
35. No impairment of contextual fear memory consolidation by oxytocin receptor antagonism in male rats.
- Author
-
Sherman, Emily R, Li, Jialu, and Cahill, Emma N
- Subjects
- *
OXYTOCIN receptors , *RATS , *MEMORY , *PEPTIDES , *FEAR , *THREAT (Psychology) , *OXYTOCIN - Abstract
• Oxytocin receptor antagonist L-368,899 didn't block aversive context conditioning. • Oxytocin receptor antagonist Atosiban didn't block aversive context consolidation. • No effect of oxytocin receptor antagonist on male rat alarm ultrasonic vocalization. Oxytocin is a peptide released into brain regions associated with the processing of aversive memory and threat responses. Given the expression of oxytocin receptors across this vigilance surveillance system of the brain, we investigated whether pharmacological antagonism of the receptor would impact contextual aversive conditioning and memory. Adult male rats were conditioned to form an aversive contextual memory. The effects of peripheral administration of either the competitive antagonist Atosiban or noncompetitive antagonist L-368,899 were compared to saline controls. Oxytocin receptor antagonism treatment did not significantly impact the consolidation of aversive contextual memory in any of the groups. We conclude that peripheral antagonism of oxytocin signalling did not impact the formation of aversive memory. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Production of Atosiban's Key Intermediate Pentapeptide: Synthetic Approaches to the Development of a Peptide Synthesis with Less Racemization and Simplifier Purification Process.
- Author
-
Ma, Chunying, Zheng, Yixuan, Liu, Jinwei, Li, Xiaobao, and Feng, Wenhua
- Subjects
- *
PEPTIDE synthesis , *RACEMIZATION , *CHROMATOGRAPHIC analysis - Abstract
The key intermediate NH2-Ile-Thr(Bzl)-Asn-Cys(Bzl)-Pro-COOH of Atosiban was prepared from N-Boc-S-Bzl-cysteine by the stepwise lengthening of the chain according to the repetitive N,O-bis(trimethylsilyl)acetamide/N-hydroxysuccinimide ester (BSA/NHS) strategy. This synthetic route required no chromatography purification and can be readily performed, yielding a highly pure pentapeptide compound. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
37. Atosiban versus ritodrine as tocolytics in external cephalic version.
- Author
-
Couceiro Naveira, Emilio and López Ramón y Cajal, Carlos
- Subjects
- *
TOCOLYTIC agents , *UTERINE contraction , *CHI-squared test , *STATISTICAL significance , *RITODRINE , *FETAL version (Obstetrics) , *BREECH delivery , *PITUITARY hormones , *LONGITUDINAL method - Abstract
Objective: To assess the efficacy of atosiban versus ritodrine as tocolytics in external cephalic version (ECV).Materials and Methods: A prospective comparative trial was carried out in a tertiary hospital. 430 women with singleton breech pregnancies ≥36 weeks were recruited for ECV, 215 with ritodrine and 215 with atosiban as tocolytic agents. The efficacy, complications and perinatal outcomes were compared between both groups. The associations between variables were analyzed using the chi-square test (χ2) (qualitative), Student's t test (quantitative, parametric) or Mann-Whitney test (nonparametric). Statistical significance was established as p < .05.Results: The overall ECV success rate was 47.9% (206/430), 46.0% in the atosiban group (99/215) and 49.8% in the ritodrine group (107/215). This difference showed no statistical significance (p = .440). A higher rate of uterine contractions after the maneuver was observed in the atosiban group (34.4 versus 22.8%; p = .008), but without clinical relevance. Perinatal outcomes were similar in both groups, with no significant differences.Conclusion: Atosiban and ritodrine showed similar efficacy as tocolytic agents in ECV, with no differences in complications and perinatal outcomes between these two agents. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
38. Is oxytocin receptor antagonist administration around embryo transfer associated with IVF treatment success? A systematic review and meta-analysis.
- Author
-
Neumann, Kay and Griesinger, Georg
- Subjects
- *
EMBRYO transfer , *OXYTOCIN receptors , *FERTILIZATION in vitro , *BIRTH rate , *RANDOMIZED controlled trials - Abstract
A systematic literature review and meta-analysis was conducted to evaluate whether the administration of an oxytocin receptor antagonist (OTR-a) around embryo transfer is associated with live birth and pregnancy achievement in IVF treatment. Multiple databases were searched for randomized controlled trials (RCT) comparing the outcome of IVF treatment with administration of an OTR-a before, during or after embryo transfer versus administration of placebo/nil. The literature search identified 11 eligible RCT. The active compound was intravenous atosiban (n = 7), subcutaneous barusiban (n = 1) and oral nolasiban (n = 3). Clinical pregnancy rate was significantly higher in women receiving an OTR-a around embryo transfer (relative risk [RR] 1.31, 95% confidence interval [CI] 1.13–1.51, P = 0.0002, I 2 = 61%, n = 11 studies, n = 3611); however, live birth rate was not statistically significantly affected (RR 1.09, 95% CI 0.98–1.20, P = 0.11, I 2 = 25%, n = 5 studies, n = 2765). A sensitivity analysis on low risk of bias studies likewise indicates a higher clinical pregnancy chance (RR 1.11, 95% CI 1.01–1.22, P = 0.03, I 2 = 5%, n = 5 RCT, n = 2765). OTR-a administration in IVF treatment has the potential to increase IVF efficacy, although the treatment effects observed so far are small and have not been sufficiently corroborated. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
39. Optimal Method for Disulfide Bond Closure in the Synthesis of Atosiban—Antagonist of Oxytocin Receptors.
- Author
-
Avdeev, D. V., Ovchinnikov, M. V., Dudkina, Y. S., Molokoedov, A. S., Azmuko, A. A., Palkeeva, M. E., and Sidorova, M. V.
- Subjects
- *
OXYTOCIN receptors , *SOLID-phase synthesis , *SOLID solutions , *POLYMER solutions , *RING formation (Chemistry) - Abstract
This work is devoted to the large-scale solid-phase synthesis (SPS) of Atosiban, Mpa1-D-Tyr(OEt)-Ile-Thr-Asn-Cys6-Pro-Orn-Gly-NH2 cyclic 1,6 disulfide, the only clinically used oxytocin receptor antagonist. The conditions have been selected for the closure of the disulfide bond (S–S) in the Atosiban molecule both in the solution and solid phase with the minimal formation of by-products. A comparative assessment of the formation of the S–S bond was carried out under various conditions. The formation of by-products during the closure of the disulfide bond has been studied both in solution and on the polymer support. The developed technique allows for the synthesis of Atosiban on an enlarged scale (10–20 mmol) involving the cyclization of a protected intermediate with the formation of the S–S bond during solid-phase synthesis with the minimal formation of by-products. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
40. Effectiveness and safety of atosiban versus conventional treatment in the management of preterm labor
- Author
-
Yan Yu, Zhi Yang, Liya Wu, Yuanfang Zhu, and Fang Guo
- Subjects
Atosiban ,Delivery ,Preterm labor ,Side effect ,Tocolytic ,Gynecology and obstetrics ,RG1-991 - Abstract
Objective: To compare the efficacy of atosiban with conventional treatment of the threatened preterm labor. Materials and methods: All the data of pregnant women with threatened preterm labor from January 1 to December 31, 2017, who received atosiban were collected. Pregnant women with conventional treatment (including β-agonists, indomethacin, magnesium sulphate and calcium channel blockers, alone or in combination) were used as control. Results: The proportion of women not requiring an alternative tocolytic treatment within 48 h and remaining undelivered was significantly higher in atosiban treatment group (89.3%; n = 25/28) compared with conventional treatment (24.2%; n = 8/33) (P
- Published
- 2020
- Full Text
- View/download PDF
41. Bryophyllum pinnatum enhances the inhibitory effect of atosiban and nifedipine on human myometrial contractility: an in vitro study
- Author
-
S. Santos, C. Haslinger, M. Mennet, U. von Mandach, M. Hamburger, and A. P. Simões-Wüst
- Subjects
Bryophyllum pinnatum ,Atosiban ,Nifedipine ,Preterm ,Myometrium ,Contractility ,Other systems of medicine ,RZ201-999 - Abstract
Abstract Background The herbal medicine Bryophyllum pinnatum has been used as a tocolytic agent in anthroposophic medicine and, recently, in conventional settings alone or as an add-on medication with tocolytic agents such as atosiban or nifedipine. We wanted to compare the inhibitory effect of atosiban and nifedipine on human myometrial contractility in vitro in the absence and in the presence of B. pinnatum press juice (BPJ). Methods Myometrium biopsies were collected during elective Caesarean sections. Myometrial strips were placed under tension into an organ bath and allowed to contract spontaneously. Test substances alone and at concentrations known to moderately affect contractility in this setup, or in combination, were added to the organ bath, and contractility was recorded throughout the experiments. Changes in the strength (measured as area under the curve (AUC) and amplitude) and frequency of contractions after the addition of all test substances were determined. Cell viability assays were performed with the human myometrium hTERT-C3 and PHM1–41 cell lines. Results BPJ (2.5 μg/mL), atosiban (0.27 μg/mL), and nifedipine (3 ng/mL), moderately reduced the strength of spontaneous myometrium contractions. When BPJ was added together with atosiban or nifedipine, inhibition of contraction strength was significantly higher than with the tocolytics alone (p = 0.03 and p
- Published
- 2019
- Full Text
- View/download PDF
42. Mechanism of Oxytocin-Induced Contraction in Rat Gastric Circular Smooth Muscle
- Author
-
Mohammad Alqudah, Rima Abdul Razzaq, Mahmoud A. Alfaqih, Othman Al-Shboul, Ahmed Al-Dwairi, and Safa Taha
- Subjects
Oxytocin ,smooth muscle contraction ,atosiban ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Oxytocin produces an excitatory effect on gastric muscle through the activation of receptors present on stomach smooth muscle cells. However, the intracellular mechanisms that mediate oxytocin excitatory effects are still largely unknown. Therefore, we aimed to investigate the signaling pathways involved in oxytocin-induced contractions in gastric smooth muscle, shedding light on phospholipase C (PLC)-β1 signaling and its downstream molecules, including inositol 1,4,5- trisphosphate (IP3) and myosin light chain kinase (MLCK). The contractions of gastric smooth muscle from male rats were measured in an organ bath set up in response to exogenous oxytocin 10−7 M, in the presence and absence of inhibitors of the indicated signaling molecules. Oxytocin (10−9–10−5 M) induced dose-dependent stomach smooth muscle contraction. Pre-incubation with atosiban, an oxytocin receptor inhibitor, abolished the oxytocin-induced contraction. Moreover, PLC β1 inhibitor (U73122) and IP3 inhibitor Xestospongin C inhibited oxytocin-induced muscle contraction to various degrees. Verapamil, a calcium channel blocker, inhibited oxytocin-induced contraction, and pre-incubation of the strips, with both verapamil and Xestospongin C, further inhibited the excitatory effect of oxytocin. Chelation of intracellular calcium with BAPT-AM (1,2-bis-(o-aminophenoxy) ethane-N,N,N′,N′-tetraacetic acid) significantly inhibited the effect of oxytocin on muscle contraction. Finally, pre-incubation of the strips with the Ca2+/calmodulin-dependent protein kinase selective inhibitor STO-609 significantly inhibited the contraction induced by oxytocin. These results suggest that oxytocin directly stimulates its cell surface receptor to activate PLC β1, which in turn liberates IP3, which eventually elevates intracellular calcium, the prerequisite for smooth muscle contraction.
- Published
- 2022
- Full Text
- View/download PDF
43. Atosiban interacts with growth hormones as adjuvants in frozen-thawed embryo transfer cycles.
- Author
-
Chen H, Cai J, Sun X, Liu L, Liu Z, Gao P, Jiang X, and Ren J
- Subjects
- Humans, Female, Pregnancy, Adult, Retrospective Studies, Growth Hormone administration & dosage, Human Growth Hormone administration & dosage, Human Growth Hormone therapeutic use, Fertilization in Vitro methods, Embryo Transfer methods, Cryopreservation methods, Pregnancy Rate, Vasotocin analogs & derivatives, Vasotocin administration & dosage
- Abstract
Objective: To investigate the interaction between atosiban and growth hormone (GH) as adjuvants in frozen-thawed embryo transfer (FET) cycles., Method: A total of 11627 patients who underwent FET at Xiamen University Affiliated Chenggong Hospital between January 2018 to December 2022 were retrospectively analyzed. Among them, 482 patients received atosiban and 275 patients received GH. The interactions were estimated by comparing the odds ratio (OR) for pregnancy comparing patients with or without atosiban adjuvant in cohorts stratified according to the presence of GH use in either the overall cohort or a propensity score (PS) matched cohort. An interaction term (atosiban × GH) was introduced to a multivariate model to calculate the ratio of OR (ORR) adjusted for confounders., Results: For all patients receiving atosiban administration, no obvious effect on pregnancy was observed in comparison with either matched or unmatched controls. However, when the patients were stratified according to GH administration, atosiban showed a significant association with clinical pregnancy in comparison with either matched or unmatched controls among patients with GH treatment with rate ratios (RR) of 1.32 (95%CI: 1.05,1.67) and 1.35 (95%CI: 1,1.82), respectively. On the other hand, however, the association was absent among patients without GH treatment. The adjusted ORRs in both matched and unmatched cohorts were 2.44 (95%CI: 1.07,5.84) and 1.95 (95%CI: 1.05, 3.49) respectively., Conclusion: The combination use of atosiban and GH in FET cycles is potentially beneficial to the pregnancy. However, indications for the use of atosiban and GH may need further assessment., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Chen, Cai, Sun, Liu, Liu, Gao, Jiang and Ren.)
- Published
- 2024
- Full Text
- View/download PDF
44. Comparison of terbutaline and atosiban as tocolytic agents in intrauterine repair of myelomeningocele: a retrospective cohort study.
- Author
-
Andrade Santos S, Souza Nani F, Imaeda de Moura E, Lima de Carvalho D, Jorge Mattos Miguel G, Maria Federicci Haddad C, Edson Vieira J, Bunduki V, Henrique Burlacchini de Carvalho M, Pulcineli Vieira Francisco R, Dante Cardeal D, and Dos Santos Fernandes H
- Subjects
- Humans, Retrospective Studies, Female, Adult, Pregnancy, Cohort Studies, Blood Gas Analysis, Terbutaline therapeutic use, Terbutaline administration & dosage, Meningomyelocele surgery, Tocolytic Agents administration & dosage, Vasotocin analogs & derivatives, Vasotocin therapeutic use
- Abstract
Background: Myelomeningocele (MMC) is a neural tube defect disease. Antenatal repair of fetal MMC is an alternative to postnatal repair. Many agents can be used as tocolytics during the in utero fetal repair such as β2-agonists and oxytocin receptor antagonists, with possible maternal and fetal repercussions. This study aims to compare maternal arterial blood gas analysis between terbutaline or atosiban, as tocolytic agents, during intrauterine MMC repair., Methods: Retrospective cohort study. Patients were divided into two groups depending on the main tocolytic agent used during intrauterine MMC repair: atosiban (16) or terbutaline (9). Maternal arterial blood gas samples were analyzed on three moments: post induction (baseline, before the start of tocolysis), before extubation, and two hours after the end of the surgery., Results: Twenty-five patients were included and assessed. Before extubation, the terbutaline group showed lower arterial pH (7.347 ± 0.05 vs. 7.396 ± 0.02 for atosiban, p = 0.006) and higher arterial lactate (28.33 ± 12.76 mg.dL
-1 vs. 13.06 ± 6.35 mg.dL-1 , for atosiban, p = 0.001) levels., Conclusions: Patients who received terbutaline had more acidosis and higher levels of lactate, compared to those who received atosiban, during intrauterine fetal MMC repair., Competing Interests: Conflicts of competing interest The authors declare no conflicts of interest., (Copyright © 2024 Sociedade Brasileira de Anestesiologia. Published by Elsevier España S.L.U. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
45. Effect of Oxytocin and Vasopressin Antagonists on Uterine Contractions (OVANCON)
- Published
- 2017
46. 阿托西班对先兆早产患者各观察指标的影响.
- Author
-
段利利, 李志斌, 张婵, 杨红, 王林, and 张娜
- Abstract
Objective To investigate the effects of atosiban combined with ritodrine hydrochloride on clinical efficacy, serological indicators and maternal and infant outcomes of patients with threatened premature delivery. Methods A total of 138 patients with threatened preterm delivery in the Department of Obstetrics and Gynecology of The First Affiliated Hospital of Air Force Military Medical University from June 2018 to June 2020 were collected and divided into two groups according to random number table method, with 69 patients in the control group treated with ritodrine hydrochloride and 69 patients in the study group treated with atosiban on the basis of the control group. Clinical efficacy, changes in serological indicators, maternal and child outcomes, and drug safety were compared between the two groups. Results There were 65 effective cases in the study group (94. 20%) and 56 effective cases in the control group (81. 16%). There were statistically significant differences between the two groups (P<0. 05). The study group had significantly shorter onset time of the drug and significantly longer duration of pregnancy than the control group (P<0. 05). Before treatment, there was no statistical difference in timp-1, il-8, il-6, NO and PGE2 levels between the two groups (P>0. 05). After treatment, timp-1, il-8, il-6, NO and PGE2 levels in the study group were significantly lower than those in the control group (P<0. 05). The success rate of fetal preservation, gestational age, neonatal weight and Apgar score were significantly higher in the study group than in the control group, while the rate of premature delivery was significantly lower than that in the control group (P<0. 05). The incidence of drug-induced adverse reactions (5. 80%) was significantly lower in the study group than in the control group (26. 09%)(P<0. 05). Conclusion Atosiban combined with ritodrine hydrochloride can effectively prolong pregnancy, reduce the level of serological indicators, improve maternal and infant outcomes, with fast effect, safe and significant efficacy. Therefore, it is worthy of application and promotion in the treatment of patients with threatened premature delivery. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
47. Oxytocin Attenuates Methamphetamine-Induced Apoptosis via Oxytocin Receptor in Rat Hippocampal Neurons.
- Author
-
Li, Chunli, Wang, Haipeng, Wang, Min, Chen, Chunyun, Bai, Fei, Ban, Mengqi, and Wu, Chunfu
- Subjects
NEURONS ,HIPPOCAMPUS (Brain) ,CENTRAL nervous system ,OXYTOCIN ,OXYTOCIN receptors ,REACTIVE oxygen species ,APOPTOSIS ,NEUROTOXICOLOGY - Abstract
Methamphetamine (METH) is a highly neurotoxic psychoactive substance that can directly damage the central nervous system through prolonged use. Oxytocin (OT) has attracted much attention because of its neuroprotective effect. The purpose of this study was to investigate whether OT is neuroprotective against METH-induced damage in rat hippocampal neurons. Our results revealed that pre-incubation with OT significantly prevented the damage of METH to hippocampal neurons, including the decrease of mitochondrial membrane potential and the increase of ROS (reactive oxygen species). OT pre-incubation attenuated the up-regulation of Cleaved-Caspase-3 expression and the down-regulation of Bcl-2/Bax expression induced by METH. Pre-incubation with OT prevented the decrease in oxytocin receptor density and P-CREB (phosphorylation of cAMP-response element binding) expression induced by METH in rat hippocampal neurons. Moreover, Pre-incubation of atosiban (ATO) significantly prevented these changes. In conclusion, our study proved that pre-administration of OT could significantly attenuate hippocampal neuron apoptosis induced by METH. Oxytocin receptor activation is involved in the preventive effect of OT on METH-induced apoptosis in rat hippocampal neurons. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
48. Randomized Trials of Retosiban Versus Placebo or Atosiban in Spontaneous Preterm Labor.
- Author
-
Saade, George R., Shennan, Andrew, Beach, Kathleen J., Hadar, Eran, Parilla, Barbara V., Snidow, Jerry, Powell, Marcy, Montague, Timothy H., Liu, Feng, Komatsu, Yosuke, McKain, Laura, and Thornton, Steven
- Subjects
- *
PREMATURE labor prevention , *OXYTOCIN , *DRUG efficacy , *RESEARCH , *TIME , *MEDICAL cooperation , *FETAL membranes , *GESTATIONAL age , *DISEASES , *PLACEBOS , *RANDOMIZED controlled trials , *COMPARATIVE studies , *TREATMENT failure , *BLIND experiment , *DELIVERY (Obstetrics) , *INFANT mortality , *PATIENT safety , *CHEMICAL inhibitors , *EVALUATION - Abstract
Objective The aim of this study is to assess the efficacy and safety of retosiban in spontaneous preterm labor (sPTL). Study Design Two multicenter, randomized, and double-blind trials compared retosiban with placebo and retosiban with atosiban in women with a singleton pregnancy and intact membranes in sPTL at 24 to 33 6/7 weeks' gestation. Coprimary endpoints in the placebo-controlled trial were time to delivery (TTD) or treatment failure (whichever occurred first) and neonatal composite morbidity and mortality. The primary endpoint of the atosiban comparator trial was TTD. Results The trials were terminated early because of slow recruitment. The placebo-controlled trial enrolled 23 participants (February 2016–July 2017; 2.6% of target);the atosiban-comparator trial enrolled 97 (March 2015–August 2017; 29% of target). Baseline participant characteristics were similar between treatments. In the placebo-controlled trial, mean gestational ages at randomization were 30.8 (retosiban, n = 10) and 30.5 weeks (placebo, n = 13), and mean times to delivery/treatment failure were 18.9 days (retosiban) and 11.1 days (placebo). Two and four neonates in the retosiban and placebo groups, respectively, had ≥1 component of the neonatal composite endpoint. In the atosiban-comparator trial, mean gestational age at randomization was 31.5 weeks (for both retosiban, n = 47, and atosiban, n = 50), and adjusted mean TTDs were 32.51 days (retosiban) and 33.71 days (atosiban; p > 0.05). Adverse events were no more common with retosiban than placebo or atosiban. Conclusion Despite considerable efforts to conduct two adequate and well-controlled studies in patients with sPTL, both studies were unable to recruit effectively and consequently terminated prematurely. Key factors negatively affecting participation were patient and physician resistance to use of a placebo comparator, lack of investigator consensus on diagnostic criteria and acceptance of protocol procedures, and ethics committee decisions. Meaningful cooperation between pharmaceutical companies, regulatory authorities, and the obstetric community is essential for future development of drugs to treat sPTL. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
49. Oxytocin Attenuates Methamphetamine-Induced Apoptosis via Oxytocin Receptor in Rat Hippocampal Neurons
- Author
-
Chunli Li, Haipeng Wang, Min Wang, Chunyun Chen, Fei Bai, Mengqi Ban, and Chunfu Wu
- Subjects
methamphetamine ,oxytocin ,atosiban ,oxytocin receptor ,hippocampal neurons ,apoptosis ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Methamphetamine (METH) is a highly neurotoxic psychoactive substance that can directly damage the central nervous system through prolonged use. Oxytocin (OT) has attracted much attention because of its neuroprotective effect. The purpose of this study was to investigate whether OT is neuroprotective against METH-induced damage in rat hippocampal neurons. Our results revealed that pre-incubation with OT significantly prevented the damage of METH to hippocampal neurons, including the decrease of mitochondrial membrane potential and the increase of ROS (reactive oxygen species). OT pre-incubation attenuated the up-regulation of Cleaved-Caspase-3 expression and the down-regulation of Bcl-2/Bax expression induced by METH. Pre-incubation with OT prevented the decrease in oxytocin receptor density and P-CREB (phosphorylation of cAMP-response element binding) expression induced by METH in rat hippocampal neurons. Moreover, Pre-incubation of atosiban (ATO) significantly prevented these changes. In conclusion, our study proved that pre-administration of OT could significantly attenuate hippocampal neuron apoptosis induced by METH. Oxytocin receptor activation is involved in the preventive effect of OT on METH-induced apoptosis in rat hippocampal neurons.
- Published
- 2021
- Full Text
- View/download PDF
50. Administration of oxytocin antagonist at the same time as using a Foley catheter with cotton swab before embryo transfer for cervical stenosis.
- Author
-
Chae, Heesuk
- Subjects
- *
EMBRYO transfer , *URINARY catheters , *OXYTOCIN , *TIME management , *STENOSIS , *UTERINE hemorrhage , *ECTOPIC pregnancy - Abstract
Background: Embryo transfer without difficulty in a patient with cervical stenosis can be a great challenge for in vitro fertilization (IVF). We report a successful pregnancy following a frozen thawed embryo transfer after administration of an oxytocin antagonist at the same time as using a Foley catheter with cotton swab in a patient with refractory cervical stenosis.Case Presentation: A 40-year-old woman undergoing IVF. The patient's previous embryo transfers were difficult. For every transfer, uterine manipulation was needed, force was required, and dilatation was necessary. A Foley catheter with a cotton swab was inserted into the cervical canal, atosiban was administered at the same time, and the Foley catheter was removed immediately before embryo transfer. A smooth transfer was performed without bleeding, force, uterine manipulation, or cervical dilator. The patient became pregnant and delivered by cesarean section at term.Conclusion: This method is effective in performing atraumatic embryo transfer in patients with cervical stenosis. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.